Circulating annexin A5 levels after atrial switch for transposition of the great arteries: relationship with ventricular deformation and geometry by Cheung, YF
Title
Circulating annexin A5 levels after atrial switch for transposition
of the great arteries: relationship with ventricular deformation
and geometry
Author(s) Cheung, YF
Citation PLOS One, 2012, v. 7, p. e52125
Issued Date 2012
URL http://hdl.handle.net/10722/180151
Rights Creative Commons: Attribution 3.0 Hong Kong License
Circulating Annexin A5 Levels after Atrial Switch for
Transposition of the Great Arteries: Relationship with
Ventricular Deformation and Geometry
Clare T. M. Lai, Pak-cheong Chow, Sophia J. Wong, Koon-wing Chan, Yiu-fai Cheung*
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
Abstract
Background: Inflammatory cytokines, cardiomyocyte apoptosis, and altered collagen turnover may contribute to
unfavourable ventricular remodeling. This unfavourable ventricular remodelling is well documented in patients after atrial
switch operation for complete transposition of the great arteries. We therefore tested if levels of circulating markers of
inflammation, apoptosis, collagen synthesis, and extracellular matrix degradation are altered in patients after atrial switch
operation for transposition of the great arteries.
Methods and Results: Circulating tumour necrosis factor (TNF)-a, annexin A5 (AnxA5), carboxy-terminal propeptide of type
I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase-1 (MMP-1), and
tissue inhibitor of metalloproteinase-1 (TIMP-1) levels were determined in 27 patients aged 25.263.1 years and 20 controls.
Ventricular myocardial deformation and left ventricular eccentricity index (EI) were determined by speckle tracking and two-
dimensional echocardiography, respectively. Compared with controls, patients had significantly higher circulating AnxA5
(p,0.001) and TNF-a (p = 0.018) levels, but similar PICP, PIIINP, MMP-1 and TIMP-1 levels. For the whole cohort, plasma
AnxA5 correlated with serum TNF-a (p = 0.002), systemic ventricular global longitudinal strain (GLS) and systolic and early
diastolic strain rate (all p,0.001), and subpulmonary ventricular GLS and early diastolic strain rate (both p,0.001). In
patients, plasma AnxA5 level correlated positively with subpulmonary ventricular EI (p = 0.027). Multiple linear regression
analysis identified systemic ventricular GLS (b=20.50, p,0.001) and serum TNF-a (b= 0.29, p = 0.022) as significant
correlates of plasma AnxA5.
Conclusions: Elevated plasma AnxA5 level in patients after atrial switch operation is associated with impaired systemic
myocardial deformation, increased subpulmonary ventricular eccentricity, and increased serum TNF-a level.
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Introduction
Progressive systemic right ventricular (RV) dysfunction in
patients after atrial switch operation for complete transposition
of the great arteries (TGA) is well documented [1–4]. Dilation of
the systemic right ventricle, alteration of septal geometry, and
compression of the subpulmonary left ventricle provide the basis
for adverse ventricular-ventricular interaction [5,6]. Proposed
mechanisms of systemic RV dysfunction after Senning or Mustard
procedure include impaired myocardial perfusion [7], myocardial
fibrosis [8], and onset of tricuspid regurgitation [1–4].
The role of inflammatory cytokines in the development of heart
failure in congenital heart disease is increasingly unveiled. In
adults with congenital heart disease, elevation of serum tumour
necrosis factor (TNF)-a level has been associated with severity of
heart failure symptoms [9]. Importantly, TNF-a has been shown
in vitro to provoke apoptosis of cardiomyocytes [9–11], decrease
collagen synthesis in cardiac fibroblasts [12], and activate matrix
metalloproteinases to degrade extracellular matrix [13,14], all of
which may contribute to unfavourable ventricular remodeling.
Experimental data suggest involvement of annexin A5 (AnxA5) in
cardiomyocyte apoptosis. [15] In hypertensive subjects, plasma
AnxA5 level is increased and shown to correlate inversely with left
ventricular (LV) systolic function [16]. Importantly, plasma and
myocardial AnxA5 levels correlate strongly and increase in a dose-
dependent manner with worsening hypertension and histological
evidence of cardiomyocyte apoptosis [16]. In patients with heart
failure undergoing cardiac resynchronization therapy, a higher
baseline plasma AnxA5 level is associated with worse LV ejection
fraction [17]. In adults with heart failure related to hypertension
and dilated cardiomyopathy, circulating biomarkers of collagen
synthesis [18,19] and extracellular matrix degradation [20–22]
have been reported. Whether these biomarkers are altered in
patients who are at risk of systemic RV dysfunction after atrial
switch operation has hitherto not been explored.
In the present study, we determined the circulating levels of
TNF-a, AnxA5, and biomarkers of collagen synthesis and
extracellular matrix degradation including carboxy-terminal
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propeptide of type I procollagen (PICP), amino-terminal propep-
tide of type III procollagen (PIIINP), matrix metalloproteinase-1
(MMP-1), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in
patients after atrial switch operation for complete TGA. We
further explored the relationships of these circulating biomarkers
with ventricular myocardial deformation and geometry.
Materials and Methods
Ethics Statement
All subjects gave written informed consent to participate in this
study approved by the Institutional Review Board of The
University of Hong Kong/Hospital Authority West Cluster, Hong
Kong.
Subjects
Twenty-seven patients with complete TGA who had undergone
Mustard or Senning procedure were recruited consecutively from
the cardiac clinic. Of these 27 patients, 18 patients had been
evaluated previously in a study on diastolic ventricular interaction
conducted 2 years ago [6] and they were invited again to have
another echocardiographic evaluation and blood examination as
detailed below. The following data were obtained from the case
notes: demographic variables, age at and type of operation,
duration of follow-up since surgery, and current cardiac medica-
tions. Twenty-two had undergone Senning operation while 5 had
Mustard procedure. Nine patients had closure of an associated
ventricular septal defect, 2 of whom had a small residual defect.
Mild baffle leak was found in 1 patient. Tricuspid regurgitation
was absent in 7 patients, trace to mild in 19, and severe in 1. Mild
subpulmonary stenosis with a Doppler-derived systolic gradient of
about 30 mmHg was noted in 2 patients. Cardiac arrhythmias
were documented in 5 patients, 2 of whom had sinus node
dysfunction, and 1 each of first degree heart block, atrial flutter,
and infrequent ventricular ectopics. All of the patients were having
a sinus rhythm at the time of echocardiographic assessment. At the
time of study, 4 patients were taking cardiac medications, which
included angiotensin-converting enzyme inhibitor or angiotensin
receptor antagonist in 4 patients, beta-blocker in 3, digoxin in 2,
and furosemide, spironolactone, sotalol, and aspirin in 1. Twenty
healthy subjects were recruited as controls. These included healthy
adult volunteers and subjects followed up in cardiac clinic for non-
specific chest pain and palpitation but without documented
organic causes. The body weight and height of all subjects were
measured, and the body mass index and body surface area were
calculated accordingly.
Echocardiographic Assessment
Transthoracic echocardiography was performed using the Vivid
7 ultrasound system (General Electric Vingmed Ultrasound,
Horten, Norway). The echocardiographic data were recorded in
digital versatile discs and analyzed offline using EchoPAC software
(General Electric, Horten, Norway). Measurements of echocar-
diographic parameters were made over three cardiac cycles and
the average was used for statistical analysis.
From the apical four-chamber view, two-dimensional speckle
tracking echocardiography was performed to determine global
longitudinal myocardial deformation of the systemic and sub-
pulmonary ventricles as described previously [6,23]. The entire
contour of the respective ventricle was traced for determination of
systolic global longitudinal strain (GLS) and global longitudinal
strain rate during systole (SRs), early diastole (SRe), and late
diastole (SRa). Our group has previously reported on a low intra-
and inter-observer variability for measurement of GLS [23].
From the parasternal short-axis view, the subpulmonary left
ventricular (LV) geometry of patients was assessed by calculating
the diastolic eccentricity index, defined as D2/D1 where D1 is the
maximum distance from the surface of the mid-ventricular septum
to that of the LV free wall and D2 is the antero-posterior distance
measured perpendicular to D1 [24].
Assay of Biomarkers
Venous blood was obtained after echocardiographic assessment
and centrifuged immediately after collection. The serum and
plasma samples were stored at 280uC until assay. Patient and
control samples were run in the same batches to minimize inter-
batch variations. Serum TNF-a level was determined by enzyme-
linked immunoassay (Quantikine HS; R&D System, Minneapolis,
USA). The standard range is 0.5–32 ng/ml and the sensitivity is
0.11 ng/ml. Plasma Annexin A5 was measured using the
commercially available Annexin V-specific ELISA (Zymutest
Annexin V, Hyphen BioMed, France) with a standard range of
0.5–10.7 mg/l and a sensitivity of 0.1 mg/l. The enzymatic
activities of serum MMP1 and TIMP1 were measured using the
Biotrak ELISA system (Amersham, GE Healthcare, Buckingham-
shire, UK). For MMP1 assay, the standard range is 6.25–100 ng/
ml with a sensitivity of 1.7 ng/ml, while for TIMP1, the standard
range is 3.13–50 ng/ml with a sensitivity of 1.25 ng/ml. Serum
PICP was measured with immunoassay (Takara Biochemicals Co,
Osaka, Japan) with a standard range of 10–640 mg/l and a
sensitivity of 2 mg/l. The plasma PIIINP was measured using
radioimmunoassay (Orion Diagnostica, Espoo, Finland) with a
standard range of 1–50 mg/l and a sensitivity of 0.3 mg/l. All
measurements were performed in duplicate and the mean was
used for further analysis.
Statistical Analysis
All data are presented as mean6standard deviation. The
demographic variables, echocardiographic parameters, and circu-
lating biomarkers of patients and controls were compared using
unpaired Student’s t test. Systemic RV strain indices in patients
were compared with systemic LV indices in controls, while
subpulmonary LV indices in patients were compared with
subpulmonary RV indices in controls. Relationships of the
circulating biomarkers found to differ significantly between
patients and controls with ventricular strain indices and geometry
were assessed using Pearson correlation analysis. Multiple linear
regression analysis was further used to identify independent
determinants of circulating biomarkers found to be significantly
elevated in patients and related to indices of ventricular
myocardial deformation. Statistical analyses were performed with
SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA). A p value less
than 0.05 was considered statistically significant while Bonferroni
adjustment was made for multiple correlational analyses.
Results
Worse Ventricular Deformation and Greater LV
Eccentricity in Patients
In order to confirm that patients after atrial repair for TGA
have unfavourable ventricular mechanics and remodelling, 27
patients (17 males) aged 25.263.1 years at 23.762.6 years after
atrial switch operation were recruited for evaluation of ventricular
myocardial deformation and LV eccentricity. The findings were
compared with those of 20 control subjects (11 males) aged
25.563.8 years (p = 0.75). The body mass index (21.863.2 kg/m2
vs 21.863.3 kg/m2, p = 0.96) and body surface area (1.760.2 m2
vs 1.760.1 m2, p = 0.39) were similar between patients and
Circulating AnxA5 after Atrial Switch for TGA
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controls. By echocardiographic assessment, patients had signifi-
cantly reduced systemic ventricular GLS and global systolic and
diastolic strain rates (all p,0.001) compared with controls
(Table 1). For the subpulmonary ventricle, the ventricular GLS
(p,0.001) and SRe (p = 0.001) were also significantly lower in
patients than controls. The morphologic left ventricle was
significantly more eccentric in patients than controls (1.960.6 vs
1.060.1, p,0.001).
Plasma AnxA5 and Serum TNF-a Levels were Higher in
Patients than Controls
Patients had significantly higher plasma AnxA5 (p,0.001) and
serum TNF-a (p = 0.018) levels than controls (Fig. 1). On the other
hand, the circulating levels of PICP (253.4671.4 ng/ml vs
275.6674.9 ng/ml, p = 0.31), PIIINP (3.961.5 ng/ml vs
4.461.2 ng/ml, p = 0.25) MMP-1 (39.569.9 ng/ml vs
34.5613.6 ng/ml, p = 0.16), and TIMP-1 (153.7636.5 ng/ml vs
156.7670.1 ng/ml, p = 0.85) were similar between patients and
controls.
Within the patient group, there were no significant differences
in the levels of these biomarkers between patients with and those
without additional VSD repair. However, patients on cardiac
medications had significantly higher plasma AnxA5 level
(2.460.6 mg/ml vs 1.860.5 mg/ml, p = 0.034) and lower sub-
pulmonary ventricular GLS (13.360.7% vs 15.563.9%,
p = 0.025) and tended to have lower systemic RV GLS
(9.761.3% vs 11.662.2%, p = 0.13) compared with those not on
medical treatments.
Significant Correlates of Plasma AnxA5 Level
For the whole cohort, plasma AnxA5 level correlated negatively
with systemic ventricular GLS (p,0.001), SRs (p,0.001), and
SRe (p,0.001), and subpulmonary ventricular GLS (p,0.001)
and SRe (p,0.001) (table 2). Among patients, plasma AnxA5
correlated significantly with subpulmonary LV eccentricity index
(r = 0.43, p = 0.027) (Fig. 2), with the correlation remaining the
same even with exclusion of the one patient with severe tricuspid
regurgitation.
Serum TNF-a level correlated positively with plasma AnxA5
level for the whole cohort (r = 0.43, p = 0.002) (Fig. 3). However,
there were no correlations between serum TNF-a level and
parameters of systemic or subpulmonary indices of ventricular
myocardial deformation (Table 2).
Multiple stepwise linear regression of the entire cohort was
performed to identify significant correlates of plasma AnxA5 level.
The independent covariates entered into the model were age, sex,
body mass index, systemic and subpulmonary ventricular GLS,
SRs, SRe, and SRa, and serum TNF-a level. The significant
independent correlates were systemic ventricular GLS (b=20.50,
p,0.001) and serum TNF-a level (b= 0.29, p = 0.022). When only
the patient cohort was analyzed with addition of duration after
operation, subpulmonary LV eccentricity and the need for cardiac
medications to the same list of covariates, the significant
determinants of plasma AnxA5 identified were LV eccentricity
index (b= 0.39, p = 0.033) and use of cardiac medications
(b= 0.37, p = 0.041).
Discussion
In the present study, we have demonstrated 1) significant
elevation of plasma AnxA5 level in Senning and Mustard patients
compared with health subjects, 2) a positive correlation between
plasma AnxA5 level and serum TNF-a concentration, and 3)
systemic ventricular strain, subpulmonary LV eccentricity, and the
use of cardiac medications to be significant determinants of plasma
AnxA5 level.
Elevation of serum TNF-a in our patients is consistent with
findings of previous studies [9,25]. In patients with a variety of
congenital heart lesions including functional single ventricles,
tetralogy of Fallot, and systemic right ventricles, Sharma et al
documented elevation of TNF-a level and its association with
worse functional status [9]. In patients with aortic stenosis, serum
TNF-a level has similarly been shown to be increased compared
with healthy subjects and related to functional class. [25]
Provocation of cardiomyocyte apoptosis and cardiac remodeling
have been demonstrated in vitro through activation of multiple
cell death pathways by TNF-a [10]. This may be of relevance in
patients after atrial switch operation who are at risk of systemic
RV dysfunction [1–4]. Our further demonstration of a positive
correlation between circulating levels of AnxA5 and serum TNF-a
is of clinical interest.
To our knowledge, this is first study to determine plasma AnxA5
level and its relationship with ventricular function and geometry in
patients with a systemic right ventricle after atrial switch operation
for complete TGA. Clinical studies on the levels and implications
of plasma AnxA5 in cardiac patients are limited. Increased plasma
AnxA5 has been reported in patients with myocardial infarction
[26–28] and unstable angina [28]. Circulating AnxA5 can be
released from injured myocardial tissue, vascular endothelial and
smooth muscle cells, secretor cells of the liver and spleen, or
apoptotic particles derived from circulating blood cells, and the
level of which has been shown to reflect severity of cell damage
[16,26–32]. The origin of increased circulating AnxA5 in our
patients is, however, unclear. In hypertensive patients with heart
failure, release of AnxA5 from the heart has been suggested by the
existence of a coronary sinus-peripheral venous AnxA5 concen-
tration gradient [16]. Whether this gradient exists in patients atrial
switch operation with systemic RV dysfunction undoubtedly
requires further study for clarification. Nonetheless, the finding
of inverse correlations between plasma AnxA5 and systolic and
diastolic ventricular strain and strain rate parameters (table 2) in
our patients perhaps lend support to the heart being a potential
Table 1. Indices of global myocardial deformation of the









GLS (%) 11.362.2 17.463.7 ,0.001*
SRs (/s) 0.6060.11 0.9760.20 ,0.001*
SRe (/s) 0.7260.18 1.3760.46 ,0.001*
SRa (/s) 0.3060.10 0.5460.24 ,0.001*
Subpulmonary ventricle
GLS (%) 15.163.7 21.265.8 ,0.001*
SRs (/s) 1.0360.28 1.1160.25 0.27
SRe (/s) 1.0560.28 1.4660.43 0.001*
SRa (/s) 0.4960.14 0.7360.72 0.16
GLS indicates global systolic longitudinal stain; SRa, global late diastolic strain
rate; SRe, global early diastolic strain rate; SRs, global systolic strain rate.
*statistically significant.
doi:10.1371/journal.pone.0052125.t001
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source. The correlations between serum TNF-a levels with AnxA5
levels but not with myocardial deformation parameters warrant
some comments. As alluded to earlier, TNF-a may act more
upstream to provoke cardiomyocyte apoptosis and cardiac
remodeling, [10] while AnxA5 may represent a more downstream
marker of this remodeling process and hence reflect more strongly
on the functional alteration of the systemic and subpulmonary
ventricles in our patients.
The mechanism underlying increased circulating AnxA5 in our
patients remains speculative. Stretch-induced up-regulation of
Figure 1. Box-plots showing (a) plasma annexin A5 (AnxA5) levels and (b) serum tumour necrosis-factor (TNF)-a levels in patients
and controls.
doi:10.1371/journal.pone.0052125.g001
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AnxA5 has been shown in non-cardiac cells [33,34]. The finding
of a correlation between subpulmonary LV eccentricity and
circulating AnxA5 level is perhaps consistent with this possibility.
A greater eccentricity of the subpulmonary left ventricle in patients
after atrial switch operation is a reflection of progressive systemic
RV dilation [5,6]. In a rodent model of pulmonary hypertension,
progression RV dilation and dysfunction are paralleled by
evidence of RV apoptosis including increased 99mTc-annexin
uptake and terminal deoxynucleotidyl-transferase-mediated dUTP
nick-end labelling [35]. Interestingly, in heart failure patients
responding to cardiac resynchronization therapy, reverse LV
remodeling is associated with reduction in plasma AnxA5 [17]. It
is tempting, therefore, to speculate that circulating AnxA5 may
possibly originate from the stretched dysfunctional systemic right
ventricle rather than the compressed left ventricle in patients after
atrial switch operation. Whether RV apoptosis plays a role in
progressive systemic RV dysfunction in Senning and Mustard
patients is a topic for further research.
Apart from the quantity of functioning contractile units,
integrity of the architectural scaffold of the myocardium is of
paramount importance for normal cardiac performance. In-
creased levels of PICP and PIIINP are found in conditions
associated with increased systemic left ventricular afterload and
dilated cardiomyopathy [36,37]. In Senning and Mustard patients,
late gadolinium enhancement in cardiac magnetic resonance
suggests increased myocardial fibrosis of the systemic right
ventricle [8]. Hence, our finding of the absence of increased
circulating biomarkers of collagen biosynthesis is surprising. It is
Figure 2. (a) Derivation of eccentricity index from a patient (right) and a control subject (left). D1 is the maximum distance from the
surface of the mid-ventricular septum to that of the LV free wall and D2 is the antero-posterior distance measured perpendicular to D1. (b) Scatter
plot showing significant correlation between subpulmonary left ventricular (LV) eccentricity index and plasma annexin A5 (AnxA5) level.
doi:10.1371/journal.pone.0052125.g002
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worthwhile noting, however, that late gadolinium enhancement of
myocardial segments probably represents a static state of regional
fibrosis [38] while circulating PICP and PIIINP may provide a
means of real-time monitoring collagen synthesis and hence the
dynamics of collagen turnover [36]. The implication of reduced
myocardial collagen synthesis in our young adult patient cohort at
the time of study is potential decline in myocardial matrix tensile
strength with the consequence of progressive systemic RV dilation
and systolic dysfunction. In this regard, TNF-a has been shown to
decrease collagen synthesis in cardiac fibroblasts in vitro [12] and
reduced serum levels of PICP and PIIINP have been reported,
albeit uncommonly, in patients with dilated cardiomyopathy [39].
Several limitations of this study warrant comments. Firstly, the
origin of the various circulating biomarkers assayed in our patients
remains to be identified. Secondly, potential confounding influ-
ences of cardiac medications on the levels of circulating
biomarkers can not completely be excluded. Nonetheless, only 4
of the 27 patients were on cardiac medications at the time of study
and we have further performed subgroup analysis based on the use
of cardiac medications. Finally, it would have been ideal to
determine the relationship between haemodynamic disturbances
as tricuspid regurgitation and subpulmonary stenosis and levels of
circulating biomarkers in a larger patient cohort.
In conclusion, this study provides the first evidence of elevated
plasma AnxA5 level in patients after atrial switch operation, which
is associated with impaired systemic myocardial deformation and
increased serum TNF-a level. The pathophysiologcal significance
of an increase in circulating AnxA5 in this adult congenital heart
population, however, requires further clarification. Serial longitu-
dinal measurement of plasma AnxA5 level with simultaneous
evaluation of clinical status and ventricular function of our patients
may shed more light on the potential role of this circulating
marker in the monitoring of systemic RV function and prognos-
tication.
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Table 2. Correlations between plasma annexin A5 (AnxA5)
and serum tumour necrosis factor (TNF)-a and parameters of
ventricular myocardial deformation.
AnxA5 TNF-a
r p r p
Systemic ventricle
GLS 20.58 ,0.001* 20.25 0.095
SRs 20.51 ,0.001* 20.27 0.071
SRe 20.53 ,0.001* 20.26 0.081
SRa 20.31 0.033 20.21 0.17
Subpulmonary ventricle
GLS 20.55 ,0.001* 20.27 0.068
SRs 20.28 0.053 20.17 0.25
SRe 20.52 ,0.001* 20.36 0.013
SRa 20.26 0.077 20.18 0.24
Abbreviations as in Table 1.
*statistically significant after Bonferroni correction.
doi:10.1371/journal.pone.0052125.t002
Figure 3. Scatter plot showing significant positive correlation between serum tumour necrosis factor (TNF)-a level and plasma
annexin A5 (AnxA5) levels (solid circles represent patients and empty circles represent controls).
doi:10.1371/journal.pone.0052125.g003
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